drugset / Trial / NCT04273256

Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial

NCT04273256

Phase 2/3 Unknown 226 enrolled American University of Beirut Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The management of poor ovarian responders (POR) remains the most challenging in In-Vitro Fertilization (IVF). The incidence of POR ranges between 9 and 24% (Caprio F, et al, 2015). POR refers to a reduction in the quantity of primordial follicle pool in reproductive age group (Jirge, P. R., 2016, Sunkara, S. K., et al, 2014), in addition to a higher risk of implantation failure (Kailasam C, et al, 2004). To overcome this condition, fertility treatments using controlled ovarian stimulation along with IVF is needed to achieve pregnancy. Despite the use of various treatments including high dose gonadotropins, patients with POR have lower rates of pregnancy compared to patients with normal ovarian response (Oudendijk, J. F., et al, 2011). Studies now suggest a variety of regimens like the use of growth hormones, DHEA or androgens to improve the outcomes (Kyrou D, et al, 2009). The main interest of this study is the use of myo-inositol prior to IVF cycles for improvement of reproductive outcomes in poor ovarian responders.

Timeline

Start
2020-02-11
Primary completion
2022-02
Completion
2023-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Inositol Small molecule 2 g

Indications